Prevention of the development and progression of renal disease

Journal of the American Society of Nephrology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Hostetter, Thomas H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; PROTEIN RESTRICTION; RISK ASSESSMENT; SCREENING;

EID: 0038544472     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.asn.0000070150.60928.06     Document Type: Conference Paper

References (24)

1. US Renal Data System: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
2. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350, 2001
3. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or met-formin. N Engl J Med 346: 393-403, 2002
4. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes. N Engl J Med 329: 977-986, 1993
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352: 837-853, 1998
6. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13-18, 1996
7. American Diabetes Association: Clinical Practice Recommendations. Diabetes Care 25[Suppl. 1]: 71-73, 2002
8. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Philips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized conrolled trial. JAMA 285: 2719-2728, 2001
9. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57: 1803-1817, 2000
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropa thy. The Collaborative Study Group. N Engl J Med 329: 14561462, 1993
11. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Long PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001
12. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl Ma, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Sanpinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
15. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program, NIH Publication No. 03-5233, 2003
16. http://www.oqp.med.va.gov/cpq/ESRD_base.htm
17. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31: 954-961, 1998
18. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomized controlled trial of dual blockage of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444, 2000
19. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117-124, 2003
20. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64-68, 2003
21. Kasiske BL: The kidney in cardiovascular disease. Ann Intern Med 134: 707-709, 2001
22. The CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287: 2542-2551, 2002
23. Trivedi HS, Pang MM, Campbell A, Saab P: Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. Am J Kidney Dis 39: 721-729, 2002
24. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 131: 660-667, 1999